Clinical Trial Update: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols [Phase 1, Phase 2]

View source ↗

Summary

An extension protocol update for subjects previously enrolled in other tivantinib (ARQ 197) protocols across Phase 1 and Phase 2 trials; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• tivantinib (tivantinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-17